Lakeside Holding (LSH) subsidiary Hupan Pharmaceutical has signed a Sales Agreement with Sinopharm Holding Hubei New Special Medicine, a subsidiary of Sinopharm Group. The agreement, valued at approximately $1.5M, is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride. This Agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSH: